PMID- 22959963
OWN - NLM
STAT- MEDLINE
DCOM- 20130220
LR  - 20211021
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 63
IP  - 8
DP  - 2012 Dec
TI  - Nicotine-induced anxiety-like behavior in a rat model of the novelty-seeking 
      phenotype is associated with long-lasting neuropeptidergic and neuroplastic 
      adaptations in the amygdala: effects of the cannabinoid receptor 1 antagonist 
      AM251.
PG  - 1335-45
LID - S0028-3908(12)00452-2 [pii]
LID - 10.1016/j.neuropharm.2012.08.016 [doi]
AB  - A rat model of the novelty-seeking phenotype predicts vulnerability to the 
      expression of behavioral sensitization to nicotine, where locomotor reactivity to 
      novelty is used to screen experimentally-naive rats for high (HR) versus low (LR) 
      responders. The present study examines the long-term neuropeptidergic and 
      neuroplastic adaptations associated with the expression of locomotor 
      sensitization to a low dose nicotine challenge and social anxiety-like behavior 
      following chronic intermittent nicotine exposure during adolescence in the LRHR 
      phenotype. Our data show that the expression of behavioral sensitization to 
      nicotine and abstinence-related anxiety are detected in nicotine pre-exposed HRs 
      even across a long (3 wks) abstinence. Moreover, these behavioral effects of 
      nicotine are accompanied by a persistent imbalance between neuropeptide Y and 
      corticotrophin releasing factor systems, and a persistent increase in 
      brain-derived neurotrophic factor (BDNF) and spinophilin mRNA levels in the 
      amygdala. Furthermore, treatment with the cannabinoid receptor 1 antagonist, 
      AM251 (5 mg/kg) during a short (1 wk) abstinence is ineffective in reversing 
      nicotine-induced anxiety, fluctuations in BDNF and spinophilin mRNAs, and the 
      neuropeptidergic dysregulations in the amygdala; although this treatment is 
      effective in reversing the expression of locomotor sensitization to challenge 
      nicotine even after a long abstinence. Interestingly, the identical AM251 
      treatment administered during the late phase of a long abstinence further 
      augments anxiety and associated changes in BDNF and spinophilin mRNA in the 
      basolateral nucleus of the amygdala in nicotine pre-exposed HRs. These findings 
      implicate long-lasting neuropeptidergic and neuroplastic changes in the amygdala 
      in vulnerability to the behavioral effects of nicotine in the novelty-seeking 
      phenotype.
CI  - Published by Elsevier Ltd.
FAU - Aydin, Cigdem
AU  - Aydin C
AD  - Charles E. Schmidt College of Medicine, Department of Biomedical Science, Florida 
      Atlantic University, 777 Glades Road, Boca Raton, FL 33431, USA.
FAU - Oztan, Ozge
AU  - Oztan O
FAU - Isgor, Ceylan
AU  - Isgor C
LA  - eng
GR  - R15 DA023675/DA/NIDA NIH HHS/United States
GR  - DA023675/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20120831
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Microfilament Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Neuropeptide Y)
RN  - 0 (Neuropeptides)
RN  - 0 (Nicotinic Agonists)
RN  - 0 (Piperidines)
RN  - 0 (Pyrazoles)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - 0 (neurabin)
RN  - 3I4FA44MAI (AM 251)
RN  - 6M3C89ZY6R (Nicotine)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
SB  - IM
MH  - Aging/psychology
MH  - Amygdala/*drug effects
MH  - Animals
MH  - Anxiety/*chemically induced/*psychology
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Corticotropin-Releasing Hormone/metabolism
MH  - Exploratory Behavior/*drug effects
MH  - In Situ Hybridization
MH  - Interpersonal Relations
MH  - Male
MH  - Microfilament Proteins/metabolism
MH  - Motor Activity/drug effects
MH  - Nerve Tissue Proteins/metabolism
MH  - Neuronal Plasticity/*drug effects
MH  - Neuropeptide Y/metabolism
MH  - Neuropeptides/*physiology
MH  - Nicotine/*pharmacology
MH  - Nicotinic Agonists/*pharmacology
MH  - Phenotype
MH  - Piperidines/*pharmacology
MH  - Pyrazoles/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, Cannabinoid, CB1/*antagonists & inhibitors
MH  - Substance Withdrawal Syndrome/psychology
PMC - PMC3697052
MID - NIHMS409820
EDAT- 2012/09/11 06:00
MHDA- 2013/02/21 06:00
PMCR- 2013/12/01
CRDT- 2012/09/11 06:00
PHST- 2011/12/06 00:00 [received]
PHST- 2012/08/15 00:00 [revised]
PHST- 2012/08/20 00:00 [accepted]
PHST- 2012/09/11 06:00 [entrez]
PHST- 2012/09/11 06:00 [pubmed]
PHST- 2013/02/21 06:00 [medline]
PHST- 2013/12/01 00:00 [pmc-release]
AID - S0028-3908(12)00452-2 [pii]
AID - 10.1016/j.neuropharm.2012.08.016 [doi]
PST - ppublish
SO  - Neuropharmacology. 2012 Dec;63(8):1335-45. doi: 10.1016/j.neuropharm.2012.08.016. 
      Epub 2012 Aug 31.